Leaps by Bayer | Activity | F4
Leaps by Bayer Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
News
Leaps published its 2025 Annual Review, highlighting $2.1+ billion total invested, 65+ portfolio companies, and 20+ new and follow-on investments in 2025. Annual Review 2025
Added recently
NuCicer introduced Nuchi, a new class of high-protein chickpeas designed for clean-label food formulation. 3 investments · JUN 2026 – JUL 2026 Show all Investment
Participated in Celea Therapeutics' $180M financing to advance deupirfenidone as a potential new standard of care for idiopathic pulmonary fibrosis. Celea Therapeutics
Investment
Participated in SonoThera's oversubscribed $125M Series B to advance ultrasound-mediated nonviral genetic medicines into clinical development. SonoThera
Investment
Co-led Leaf Agriculture's $13M Series B to bring AI-powered data integration to agribusiness. Leaf Agriculture
4 milestones · OCT 2025 – JAN 2026 Show all Milestone
Bayer and Soufflé Therapeutics announced a strategic collaboration to advance cell-specific heart-targeted siRNA therapy. Soufflé Therapeutics
Milestone
Pairwise licensed its CRISPR platform to the International Rice Research Institute to advance climate-resilient, nutritious rice varieties. Pairwise
Milestone
Fork & Good acquired Orbillion to take its cultivated red meat platform global. Fork & Good
Milestone
Sudo Biosciences announced positive Phase 1 results for brain-penetrant allosteric TYK2 inhibitor SUDO-550. Sudo Biosciences
Investment
Dewpoint Therapeutics closed Series D to advance first-in-class condensate modulator into clinical development for gastric cancer. Dewpoint Therapeutics
Milestone
eGenesis received IND clearance for EGEN-2784 in kidney transplant and announced landmark patient updates in its xenotransplantation expanded access study. eGenesis
Exit
AbbVie announced acquisition of Capstan Therapeutics, a Leaps portfolio company focused on precise in vivo cell engineering for immunology. Capstan Therapeutics
Milestone
BlueRock Therapeutics advanced bemdaneprocel, an investigational cell therapy, to a registrational Phase III clinical trial for Parkinson's disease. BlueRock Therapeutics
Milestone
Bayer and Dewpoint Therapeutics signed a licensing agreement for a heart disease program based on condensate biology. Dewpoint Therapeutics